DHEA-S Sex- and Cycle-Related Differences: Normal Ranges, Optimal Levels, and What They Mean

DHEA-S (dehydroepiandrosterone sulfate) is the sulfated storage form of DHEA, an adrenal androgen precursor. It is not the same molecule as unconjugated DHEA, which circulates at much lower concentration and has a far shorter half-life. DHEA-S is produced almost entirely by the adrenal cortex, with a small contribution from the gonads in premenopausal women and in men. Because it is not tightly bound to sex-hormone-binding globulin and clears slowly, a single blood draw gives a reasonably stable read on adrenal androgen output, unlike cortisol or LH, which move throughout the day.

The useful question for most readers is not "is my DHEA-S normal" but "normal for whom, at what age, on what day of the cycle, and measured by which assay." A DHEA-S value that looks low against a generic adult range can be entirely expected for a 55-year-old, alarming for a 25-year-old, or an artifact of luteal-phase timing or recent hormonal contraceptive use. This article lays out sex- and age-specific ranges, what changes across the menstrual cycle, and where the evidence for "optimal" targets is solid versus speculative.

A concise summary of the evidence: DHEA-S is markedly higher in men than in women at every adult age, peaks around the mid-20s in both sexes, and declines steadily thereafter (a pattern sometimes called adrenopause). Reference intervals vary by laboratory and by assay platform, so no single numeric range applies everywhere. Cycle-phase changes in women are real but modest compared with estradiol or LH, and combined hormonal contraceptives suppress DHEA-S. Low DHEA-S has been associated with adverse cardiovascular and metabolic outcomes in observational cohorts, but this has not been established as causal, and DHEA supplementation has not consistently reproduced those associations in randomized trials.

What DHEA-S measures, and why the sulfate form matters

Unconjugated DHEA is converted to DHEA-S by sulfotransferase enzymes, mainly in the adrenal gland and liver, and the two forms interconvert. DHEA-S circulates at concentrations roughly two to three orders of magnitude higher than free DHEA, which is why it is the form measured clinically. Peripheral tissues (skin, bone, breast, prostate, and others) can cleave the sulfate group locally and use the resulting DHEA as a precursor for tissue-level androgens and estrogens, a pathway generally described as intracrine steroid production. This means DHEA-S can influence tissue biology in ways that a standard circulating sex-steroid panel does not directly capture, though the clinical significance of this pathway in an individual patient is not something a lab value alone can quantify.

Assay method affects the number you get back

Different laboratory platforms (older immunoassays versus liquid chromatography-tandem mass spectrometry, LC-MS/MS) can report different absolute DHEA-S values for the same sample, and reference intervals are platform-specific. If you are comparing a result to a published range, or comparing two results from different labs over time, confirm both used a comparable method. This is a general limitation of steroid immunoassays that has been described in the endocrine literature and should be treated as a caution rather than a precise correction factor unless your lab specifies one.

Reference ranges by sex and age

Ranges below are typical adult laboratory reference intervals reported in commercial and academic lab compendia. They are illustrative, not a substitute for the specific reference range printed on your own lab report, which reflects that lab's assay, population, and units.

Men

Women

The consistent pattern across cohorts is that men run higher than women at every decade, both sexes peak in the mid-20s, and both decline afterward. The specific boundary numbers above should be treated as approximate; they will not match every lab's printed range exactly, and a value slightly outside these bands is not automatically abnormal.

Menstrual cycle variation

DHEA-S does not show the sharp mid-cycle surge seen with LH or estradiol, but daily-sampling studies of the menstrual cycle have described a modest pattern: DHEA-S tends to run somewhat higher in the early follicular phase and somewhat lower in the luteal phase. The magnitude reported in the literature is meaningfully smaller than the cycle swings seen in estradiol, but it can be large enough to move a borderline result across a reference-range boundary. The exact percentage of within-cycle variation varies between studies and populations; readers should treat any specific percentage as approximate until confirmed against the primary study for their own lab's method.

Practical implication: for reproducibility, premenopausal women who want to compare DHEA-S over time, or interpret it alongside FSH and estradiol, should draw the sample on the same cycle days each time, commonly days 3 through 7, which is the convention used in fertility and adrenal-function workups. Postmenopausal women and women on hormonal contraception can test on any day, since cycle-driven variation does not apply.

Hormonal contraception

Combined oral contraceptives suppress ovarian and, to a lesser extent, adrenal androgen output through LH suppression and estrogen-driven changes in binding globulins. The result is a lower DHEA-S while on the pill, and values may remain lower for a period after stopping. If you are being evaluated for an androgen disorder or adrenal insufficiency, note your contraceptive history and timing on the requisition, and expect your clinician to interpret the result in that context rather than against a generic range.

Age-related decline (adrenopause)

DHEA-S decline with age is one of the most consistently reproduced findings in endocrinology: levels fall steadily from a mid-20s peak, and by the seventh or eighth decade most people have levels well below their own peak. This decline occurs in both sexes and does not track tightly with other clinical variables such as body weight or smoking in the studies that have examined it. Unlike menopause, there is no defined clinical threshold for "adrenopause" and no professional society consensus on treating it.

What the cardiovascular and mortality data show, and do not show

Several prospective cohort studies conducted over recent decades have reported associations between lower DHEA-S and higher cardiovascular or all-cause mortality risk, and a pooled analysis of multiple cohorts has reported a similar direction of association. These are observational findings. They establish an association, not a causal mechanism, and DHEA-S may simply be a marker of overall physiologic reserve rather than a protective hormone in its own right. Randomized trials of DHEA supplementation in older adults have not consistently reproduced improved cardiovascular outcomes, which is the standard reason clinicians are cautious about treating a low DHEA-S purely to "correct the number." Specific relative-risk or hazard-ratio figures from individual studies are not reproduced here because they require verification against the primary papers before being presented as precise; a clinician or medical reviewer should confirm any such figure before it is used in patient-facing material.

A decision framework for interpreting a DHEA-S result

Because "normal" depends on sex, age, cycle timing, medication status, and symptoms, a single cutoff is not useful. This framework walks through the questions that actually change what a given result means and what, if anything, should happen next. It is an educational aid, not a diagnostic algorithm, and does not replace a clinician's judgment.

Step 1: Confirm the comparison is fair.

• Is the reference range on the report sex-specific and age-band specific? If not, request one or compare against a published age/sex table rather than a single blanket adult range.
• Was the sample drawn on a comparable day if the patient is a premenopausal woman? A result outside range drawn on day 24 of the cycle may sit inside range if repeated on day 4.
• Is the patient on combined hormonal contraception, recently stopped it, or on any glucocorticoid? Any of these can shift DHEA-S independent of adrenal reserve.
• Was biotin supplementation recently taken? High-dose biotin can interfere with some immunoassay platforms; check with the lab if the patient takes biotin and the result is unexpected.

Step 2: Locate the result in context, not just against the range boundary.

• A value in the lower third of the age- and sex-specific range, without symptoms, is generally not actionable on its own.
• A value below the lower boundary of the age-specific range, especially in someone under 40, is a reason to investigate further rather than to assume normal aging.
• A value clearly above the upper boundary (roughly above 500 mcg/dL in women or 700 mcg/dL in men, pending confirmation against your lab's own scale) warrants evaluation for an androgen-secreting adrenal process, particularly if accompanied by rapid-onset hirsutism, virilization, or other signs of excess androgen.

Step 3: Match the pattern to a plausible cause before acting.

• Low DHEA-S plus fatigue, hypotension, hyperpigmentation, or electrolyte abnormalities: this combination should prompt assessment of the broader adrenal axis (morning cortisol, and if borderline, formal stimulation testing) rather than DHEA-S in isolation. DHEA-S alone does not diagnose or exclude adrenal insufficiency.
• Low DHEA-S as an isolated finding in someone over 50 with no adrenal symptoms: most likely reflects expected age-related decline; discuss whether monitoring or supplementation is appropriate based on symptoms, not the number alone.
• High DHEA-S with hirsutism, irregular cycles, or acne in a premenopausal woman: consider polycystic ovary syndrome or non-classic congenital adrenal hyperplasia as more common explanations before assuming a tumor, and compare with total and free testosterone to gauge how much of the picture is adrenal versus ovarian.
• High DHEA-S with rapid symptom onset, very high absolute values, or signs of virilization: this pattern is the one that should prompt urgent adrenal imaging rather than reassurance, given the (rare but real) possibility of an adrenocortical tumor.

Step 4: Decide whether supplementation is even the right question.

• DHEA supplementation has clearer, guideline-referenced support in women with confirmed adrenal insufficiency, where it may help mood and sexual function; this is a distinct clinical scenario from "low-normal aging."
• For otherwise healthy aging adults with a low but age-expected DHEA-S and no adrenal insufficiency, the evidence for supplementation improving hard outcomes (cardiovascular events, mortality, bone fracture) is suggestive at best and not established. This is a shared decision between patient and clinician, not an automatic prescription triggered by a lab number.
• Any decision to supplement should include a follow-up level (commonly proposed around 8 to 12 weeks later) to confirm the intended range is reached without overshoot, and monitoring for androgenic side effects (acne, hirsutism, voice change, mood change).

DHEA-S in polycystic ovary syndrome (PCOS)

DHEA-S is one of the androgens measured when evaluating hyperandrogenism in women, because it is almost entirely adrenal in origin, in contrast with testosterone and androstenedione, which reflect a mix of adrenal and ovarian sources. In practice, a woman with an elevated DHEA-S but normal testosterone is showing predominantly adrenal androgen excess, while elevated testosterone with normal DHEA-S points more toward an ovarian source. PCOS guidelines describe DHEA-S testing as useful for this distinction and for screening for an adrenal tumor in women being evaluated for hyperandrogenism; the exact wording of any specific society guideline should be verified against the primary document before being quoted directly in patient materials. General background on PCOS is available from the CDC.

DHEA-S in men on testosterone replacement therapy

Testosterone replacement therapy (TRT) suppresses the hypothalamic-pituitary-gonadal axis (LH and FSH), which reduces testicular testosterone production, but it does not directly suppress ACTH-driven adrenal DHEA-S production. In practice this means DHEA-S can continue its age-related decline in a man on TRT even while his measured total testosterone looks stable or improved, because exogenous testosterone is masking the gonadal side of the picture without correcting adrenal aging. For this reason, some clinicians monitor DHEA-S periodically in men over 45 on TRT as a separate signal of adrenal reserve, distinct from testosterone dosing adequacy. Cross-sectional data have also linked lower DHEA-S with markers of insulin resistance and metabolic syndrome in men independent of testosterone status, though this is an association from observational data, not a demonstrated causal or treatable pathway.

How the test is done and what it cannot tell you

A single morning fasting blood draw is standard; DHEA-S has low diurnal variation compared with cortisol, so exact draw time is less critical than for a cortisol test, though morning draws standardize comparison across repeat tests. High-dose biotin (vitamin B7) supplementation can interfere with some immunoassay-based hormone tests and should generally be paused for a day or two before the draw if your lab uses an immunoassay platform; check with the specific lab if unsure.

DHEA-S does not measure cortisol axis function, does not diagnose or exclude adrenal insufficiency on its own, and "adrenal fatigue" is not a recognized diagnosis in mainstream endocrinology. A low DHEA-S in someone with concerning symptoms (fatigue, hypotension, weight loss, hyperpigmentation) should prompt a morning cortisol and, if indicated, formal adrenal axis testing, rather than being treated as a stand-alone diagnosis.

Evidence boundary: what is established, what is plausible, what is not

Established: DHEA-S is higher in men than women across adulthood, peaks in the mid-20s, and declines steadily with age in both sexes. It is markedly reduced by combined hormonal contraceptive use. It is useful for distinguishing adrenal from ovarian sources of androgen excess. Reference ranges differ by assay platform and by laboratory.

Plausible but not established: That raising DHEA-S toward "upper-quartile, 30-year-old" targets through supplementation improves hard outcomes such as cardiovascular events, fracture, or mortality in adults without adrenal insufficiency. Observational associations between low DHEA-S and adverse outcomes are consistent across several cohorts, but randomized supplementation trials have not reliably reproduced a benefit on hard endpoints.

Not established: A single universal "optimal" numeric target that applies regardless of symptoms, sex, and clinical context. The specific magnitude of many quoted statistics in this field (exact percentage cycle variation, exact relative-risk figures from individual cohort studies, exact trial-level laboratory changes) varies across sources and should be confirmed against the primary paper before being used as a precise, citable figure in clinical communication.